Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Becton, Dickinson and Company
ClinicalTrials.gov Identifier:
NCT01557907
First received: March 9, 2012
Last updated: July 25, 2012
Last verified: July 2012
  Purpose

The primary objective of this study is to investigate if intradermal (in the skin) basal and bolus insulin delivery of a fast acting insulin analog (NovoRapid) as needed to adequately control the blood glucose for a subject with Type 1 Diabetes can be maintained for a period of up to three days and if intradermal delivery of insulin has advantages over standard subcutaneous (under the skin) delivery.


Condition Intervention Phase
Diabetes
Device: Subcutaneous delivery via Medtronic Quick-Set
Device: Intradermal delivery via the BD Research Catheter Set
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multi-day (3) In-patient Evaluation of Intradermal vs Subcutaneous Basal/Bolus Insulin Infusion

Resource links provided by NLM:


Further study details as provided by Becton, Dickinson and Company:

Primary Outcome Measures:
  • Insulin levels [ Time Frame: 0,10,15,20,25,30,35,40,45,50,55,60,65,70,80,90,120,150,180,210,240,300,330,345,360 minutes following each breakfast and lunch meal bolus for the 3 study days ] [ Designated as safety issue: No ]
    Time to peak plasma concentration (Tmax) of insulin delivered intradermally as compared to insulin delivered subcutaneously after a meal bolus.


Secondary Outcome Measures:
  • Insulin levels [ Time Frame: 0,10,15,20,25,30,35,40,45,50,55,60,65,70,80,90,120,150,180,210,240,300,330,345,360 minutes following each breakfast and lunch meal bolus for the 3 study days ] [ Designated as safety issue: No ]

    Comparison of peak plasma concentration (Cmax) of insulin, intradermally versus subcutaneously, during a meal bolus period.

    Comparison of area under the plasma concentration versus time curve (AUC), intradermally versus subcutanously, during a meal bolus period.


  • Blood Glucose [ Time Frame: 0,10,15,20,25,30,35,40,45,50,55,60,65,70,80,90,120,150,180,210,240,300,330,345,360 minutes following each breakfast and lunch meal bolus for the 3 study days ] [ Designated as safety issue: No ]

    Peak concentration of blood glucose (BGmax) during post meal excursions periods.

    Area under the plasma concentration versus time curve (AUC) of blood glucose during post meal excurion periods.


  • Device performance - adhesion [ Time Frame: Evaluated at every timepoint a bolus injection is given ] [ Designated as safety issue: No ]
    Adhesion (device remains attached to the skin) will be evaluated over the 3 day study period (adhered well, partially adhered, completely pulled off).

  • Skin thickness using ultrasound [ Time Frame: Upon removal of the device (within 5 minutes) ] [ Designated as safety issue: No ]
    Skin thickness will be measured at the infusion site and a control site using ultrasound

  • Device performance - Leakage of fluid (insulin) at injection site [ Time Frame: Immediatley before and after each bolus injection and immediatly upon removal of the device at the end of the study period. ] [ Designated as safety issue: No ]
    Immediatley before and after each bolus injection, the site will be observed for leakage (insulin). In addition, following removal of the device, if leakakge is observed, the fluid will be collected and quantified using a gravimetic method procedure. Leakage will be collected using a pre-weighed sterile absorbent swab, the swab will be re-weighed and the collected fuid volume calculated based on the density of the fluid.

  • Device performance-pump alarm [ Time Frame: over the 3 study days ] [ Designated as safety issue: No ]
    The presence of an auditory alarm indicating an occlusion will be noted.

  • Skin effects-Draize Scoring for Skin Irritation [ Time Frame: Following removal of the device (within 2 minutes) and 1 and 2 hours (+/- 5 minutes) post removal. ] [ Designated as safety issue: No ]
    Local reaction at injection site will be scored using the Draize Scale 0-4 for redness and 0-4 for swelling.

  • Number of participants with adverse events [ Time Frame: up to 53 days or until the subject is discharged, if sooner. ] [ Designated as safety issue: Yes ]
    At each study contact, subjects will be questioned about any new or worsening undesirable events.


Enrollment: 23
Study Start Date: February 2012
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intradermal - BD Research Catheter Set
Intradermal delivery of insulin (basal and bolus delivery) using the BD Research Catheter Set with 34G x 1.5 mm side-ported needle and the Animas Vibe insulin pump over a three day period.
Device: Intradermal delivery via the BD Research Catheter Set
Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
Other Names:
  • microneedles
  • insulin infusion set
Active Comparator: Subcutaneous - Medtronic Quick-Set
Subcutaneous delivery of insulin (basal and bolus delivery) using the Medtronic Quick Set with 6 mm Teflon catheter and the Animas Vibe insulin pump over a three day period.
Device: Subcutaneous delivery via Medtronic Quick-Set
Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
Other Name: insulin infusion set

Detailed Description:

The is a single center, open-label, 2 period crossover study randomized by route (intradermal versus subcutaneous) in patients with Type 1 diabetes. Subjects will receive their insulin, basal and bolus dosages, via intradermal (ID) and subcutaneous (SC) infusion sets over a three day period.

Each subject will participate in 3 visits: a Screening Visit (V1), followed by 2 experimental intervention days (V2 and V3) to be started 2 - 21 days after screening visit. The minimum/maximum interval between study days shall be 5 to 28 days. Each subject will remain in the clinic for approximately 3 days during the experimental interventions. A final exam will be performed at the end of Visit 3.

After successful screening and enrollment subjects are admitted to the clinic. Their insulin pump and infusion set is replaced by the investigational system, a commercially available insulin pump and either the intradermal infusion set (Research Catheter Set, BD) or the subcutaneous infusion set (Quick Set, Medtronic)to include an in-line pressure transducer/recorder and insulin NovoRapid. The initial pump infusion rate is established based on the patient's known basal infusion rate and the meal bolus insulin is estimated based on the patient's known insulin sensitivity. An intravenous (in the vein) catheter line is established, blood glucose is measured at least every 2 hours overnight and insulin corrections can be implemented, if deemed necessary. The overnight and pre-prandial (before meal) target range is 70-160 mg/dl, although the procedure will continue as planned if the patient is outside the range. It should be the goal not to give any IV glucose or insulin at all, and not to change basal insulin settings for at least 2 hours before the meal. The breakfast meal will be a high GI (60g carbohydrates) solid meal, to be consumed within 15 minutes and followed for a period of 6 hours of blood sampling for glucose and insulin levels. Lunch will be served as standardized mixed meal, and followed for a period of 4-6 hours. This procedure is repeated on days 2 and 3 whereas the breakfast and lunch meal as well as the insulin dose to cover the meal are the same. A light evening dinner is served every day, composition and insulin dose to be recorded. On day three after the 4 hour period following lunch the catheter will be removed, catheter and site assessments will be documented and an ultrasound observation of the infusion site (skin thickness and SC) versus an adjacent control site will be performed within 10 min after removal of the infusion set. Glucose rescue, if necessary, will be administered orally (juice, 200 mL). Insulin correction boli should be delivered via the investigational infusion set.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

Male and Female patients will be included in the trial only if they fulfill all the inclusion criteria mentioned below:

  • Understood and signed informed consent obtained before any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the patient)
  • Type 1 Diabetes mellitus, according to clinical judgment / ADA / WHO-definition (Diabetes Care 2003; 26: 5-20) for at least 1 year.
  • Usage of insulin pump therapy (CSII) with carb counting for at least six months
  • Age in the range of ≥ 18 and ≤ 55 years
  • Body mass index (BMI) ≤ 32 kg/m²
  • HbA1c ≤ 8.0% at screening
  • Using ≤ than 60 U of insulin on a typical day (preferably)
  • Able and willing to adhere to the study procedures for the entire trial period
  • Negative test results for hepatitis C antibodies, hepatitis B surface antigen and HIV at screening.

EXCLUSION CRITERIA

Patients will not be permitted to enter the trial, if they fulfill any of the exclusion criteria mentioned below:

  • Previous participation in this trial or participation in a clinical trial within 3 months prior to screening examination
  • Any symptoms suggestive of, or a diagnosis or treatment for gastroparesis
  • Abnormalities in renal function (e.g. serum creatinine > 120 µmmol/L for male, >100 µmmol/L for female subjects or judged by the investigator that would pose a problem of clearance of injected insulin
  • Proliferative retinopathy or maculopathy that has required acute treatment within the last six months
  • Acute and severe illness apart from diabetes mellitus as judged by the investigator
  • Abnormalities in the laboratory parameters if judged as clinically significant by the investigator. In particular, patients with GOT/GPT > 3 x upper limit of normal (ULN), thrombocyte count <100/nL, INR >1.3, PTT >50 sec.
  • Clinically significant abnormalities in the ECG
  • Recurrent major hypoglycemia or hypoglycemic unawareness as judged by the investigator
  • Lipodystrophy which in the judgment of the investigator would pose a problem in terms of variability of absorption of injected insulin
  • Use of systemic corticoids for the last three month prior screening examination or treatment with medication known to interfere with glucose metabolism such as non-selective ß-blockers, or mono amine oxidase (MAO) inhibitors, ACE-inhibitors or thiazides, unless such medical treatment has existed for at least three months and is not changing, prior to screening examination
  • Any disease requiring use of anti-coagulants
  • Impaired hepatic or renal functions as judged by the investigator
  • Cardiac problems as judged by the investigator
  • Uncontrolled hypertension (treated or untreated) RRsyst. >140 mmHg, RRdiast. > 90 mmHg
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation
  • Current addiction to alcohol or substances of abuse as determined by the investigator
  • Allergy to plaster/adhesive
  • Any other condition that the investigator feels would interfere with trial participation or evaluation of results.
  • Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures include sterilisation, hormonal intrauterine devices, oral contraceptives, sexual abstinence or vasectomised partner)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01557907

Locations
Germany
Profil Institut fur Stoffwechselfforschung GmbH
Neuss, Germany, D-41460
Sponsors and Collaborators
Becton, Dickinson and Company
Investigators
Principal Investigator: Christoph Kapitza, MD Profil Institut fur Stoffwechselforschung (GmbH)
  More Information

No publications provided

Responsible Party: Becton, Dickinson and Company
ClinicalTrials.gov Identifier: NCT01557907     History of Changes
Other Study ID Numbers: BDT-11-ADC001
Study First Received: March 9, 2012
Last Updated: July 25, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Becton, Dickinson and Company:
Diabetes
Diabetes Mellitus
Type 1 diabetes
Insulin Pump users
Intradermal insulin

Additional relevant MeSH terms:
Insulin, Globin Zinc
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 16, 2014